BR112012017319A2 - composições e métodos para abaixar a pressão intraocular - Google Patents

composições e métodos para abaixar a pressão intraocular

Info

Publication number
BR112012017319A2
BR112012017319A2 BR112012017319A BR112012017319A BR112012017319A2 BR 112012017319 A2 BR112012017319 A2 BR 112012017319A2 BR 112012017319 A BR112012017319 A BR 112012017319A BR 112012017319 A BR112012017319 A BR 112012017319A BR 112012017319 A2 BR112012017319 A2 BR 112012017319A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
intraocular pressure
lowering
lowering intraocular
Prior art date
Application number
BR112012017319A
Other languages
English (en)
Inventor
Chetan P Pujara
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43743470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012017319(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112012017319A2 publication Critical patent/BR112012017319A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composições e métodos para abaixar a pressão intraocular. a presente inveção refere-se a composições para abaixar a pressão intraocular (iop) de um olho compreendendo uma combinação de agentes de abaixamento de iop bimatoprost, brimonidina, e timolol. adicionalmente revelados são métodos para reduzir iop no olho de um indivíduo.
BR112012017319A 2009-12-22 2010-12-21 composições e métodos para abaixar a pressão intraocular BR112012017319A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28893609P 2009-12-22 2009-12-22
US36174910P 2010-07-06 2010-07-06
PCT/US2010/061563 WO2011087790A1 (en) 2009-12-22 2010-12-21 Triple combination for lowering intraocular pres sure

Publications (1)

Publication Number Publication Date
BR112012017319A2 true BR112012017319A2 (pt) 2016-04-19

Family

ID=43743470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017319A BR112012017319A2 (pt) 2009-12-22 2010-12-21 composições e métodos para abaixar a pressão intraocular

Country Status (15)

Country Link
US (1) US20130116254A1 (pt)
CN (1) CN102695498A (pt)
AR (1) AR079696A1 (pt)
BR (1) BR112012017319A2 (pt)
CL (1) CL2012001736A1 (pt)
CO (1) CO6592061A2 (pt)
CR (1) CR20120360A (pt)
EC (1) ECSP12012033A (pt)
GT (1) GT201200213A (pt)
IN (1) IN2012DN06416A (pt)
MX (1) MX2012007397A (pt)
NI (1) NI201200112A (pt)
PE (2) PE20160904A1 (pt)
TW (1) TW201143773A (pt)
WO (1) WO2011087790A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
AU2011282683B2 (en) 2010-07-29 2016-12-22 Allergan, Inc. Preservative free brimonidine and timolol solutions
WO2013163219A1 (en) * 2012-04-24 2013-10-31 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
KR20170129823A (ko) * 2015-03-19 2017-11-27 알러간, 인코포레이티드 브리모니딘 및 티몰롤의 고정된 용량 조합
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
US12042502B2 (en) * 2022-03-21 2024-07-23 Somerset Therapeutics, Llc Enhanced penetration ophthalmic compositions of bimatoprost and timolol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution

Also Published As

Publication number Publication date
NI201200112A (es) 2013-04-09
PE20121468A1 (es) 2012-10-28
CL2012001736A1 (es) 2012-10-12
CR20120360A (es) 2012-07-30
WO2011087790A1 (en) 2011-07-21
TW201143773A (en) 2011-12-16
US20130116254A1 (en) 2013-05-09
PE20160904A1 (es) 2016-09-16
GT201200213A (es) 2014-08-29
CN102695498A (zh) 2012-09-26
AR079696A1 (es) 2012-02-15
ECSP12012033A (es) 2012-10-30
MX2012007397A (es) 2012-08-15
CO6592061A2 (es) 2013-01-02
IN2012DN06416A (pt) 2015-10-09

Similar Documents

Publication Publication Date Title
UA102257C2 (uk) Офтальмологічний водний розчин для лікування очної гіпертензії та глаукоми
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
AU2012307812A8 (en) Ophthalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
BR112012017319A2 (pt) composições e métodos para abaixar a pressão intraocular
EA201290097A1 (ru) Спиртовые композиции, имеющие пониженный риск возникновения ацетальдегидемии
IN2012DN06581A (pt)
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
IT1393402B1 (it) Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali
MY171920A (en) Prevention and treatment of ocular conditions
WO2007111806A3 (en) Cyclopentane heptanoic acid compounds for reducing body fat
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
MY150855A (en) Oral compositions containing extracts of zizyphus joazeiro and related methods
EP3653205A3 (en) Oxymethazoline for topical ophthalmic administration and uses thereof
EP2515917A4 (en) COMPOSITIONS AND METHODS FOR EYE-UP
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
MY159244A (en) Method of reducing intraocular pressure in humans
TW200738651A (en) Cyclohexyl sulfonamide derivatives
WO2013006335A3 (en) Methods and compositions useful for treating fitzpatrick type iv, v or vi skin
MX2014000781A (es) Dosis combinada fija de bimatoprost y brimonidina.
TR201818754T4 (tr) Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
MY160383A (en) Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
WO2009109501A3 (en) Ocular pharmaceutical compositions
IT1398378B1 (it) Citicolina per il trattamento del glaucoma e dell'ipertensione oculare.
BRPI1003940B8 (pt) Composição para cuidado de saúde compreendendo um tensoativo polimerizado de baixo dp e um espessante micelar

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]